<unk>  is an kinase inhibitor that is FDA approved for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.   Common adverse reactions include thrombocytopenia, diarrhea, neutropenia, anemia, fatigue, musculoskeletal pain, peripheral edema, upper respiratory tract infection, nausea, bruising, dyspnea, constipation, rash, abdominal pain, vomiting and decreased appetite ..
Ibrutinib
Bosutinib
Acalabrutinib
Ruxolitinib
Afatinib
Neratinib
Ceritinib
Dasatinib